title: Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase.
abstract: BACKGROUND
  It is uncertain which people with chronic myelogenous leukemia (CML) in chronic phase should receive conventional treatment (interferon and/or chemotherapy) versus high-dose therapy and a bone marrow transplant. There are no randomized trials comparing these approaches and analyses of data from non-randomized studies are complex, contradictory without sufficient detail to allow subject-level treatment decisions.
  
  
  OBJECTIVE
  Determine appropriateness of high-dose therapy and bone marrow transplants in persons with CML in chronic phase with specific features. Develop a treatment algorithm. PANELISTS: nine leukemia experts from diverse geographic sites and practice settings.
  
  
  METHODS
  Boolean MEDLINE searches of chronic myelogenous leukemia and chemotherapy and/or transplants.
  
  
  METHODS
  We used a modified Delphi-panel group judgment process. Age, prognostic score, disease duration, and type of conventional therapy and response were permuted to define 90 clinical settings. Each panelist rated appropriateness of high-dose therapy and a transplant versus conventional therapy on a 9-point ordinal scale (1, most inappropriate, 9, most appropriate) considering three types of donors: (1) HLA-identical siblings; (2) alternative donors (HLA-matched related or unrelated people other than an HLA-identical sibling); and (3) autotransplants. An appropriateness index was developed based on median rating and amount of disagreement. Relationship of appropriateness indices to permuted clinical variables was considered by analysis of variance and recursive partitioning. Preference between donor types was analyzed by comparing mean appropriateness indices of similar settings and a treatment algorithm developed.
  
  
  CONCLUSIONS
  In people with CML in chronic phase and an HLA-identical sibling donor and in those with an alternative donor (but no HLA-identical sibling), a transplant was rated appropriate in those with a < or = partial cytogenetic response to interferon and uncertain or inappropriate in all other settings. Autotransplants were rated uncertain or inappropriate in all settings. Most of the variance in appropriateness ratings between different clinical settings was accounted for by response to interferon: complete versus < or = partial response. An HLA-identical sibling donor, when available, was always preferred to an alternative donor or autotransplant. In people without an HLA-identical sibling, an alternative donor was favored over an autotransplant at higher appropriateness indices and the converse at lower appropriateness indices.
authors.affiliation: Salik Health Care, Inc., Los Angeles, CA 90048-4520, USA. rgale@salick.com
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
authors.forename: R E
authors.initials: RE
authors.lastname: Park
authors.forename: R W
authors.initials: RW
authors.lastname: Dubois
authors.forename: G P
authors.initials: GP
authors.lastname: Herzig
authors.forename: W G
authors.initials: WG
authors.lastname: Hocking
authors.forename: M M
authors.initials: MM
authors.lastname: Horowitz
authors.forename: A
authors.initials: A
authors.lastname: Keating
authors.forename: S
authors.initials: S
authors.lastname: Kempin
authors.forename: C A
authors.initials: CA
authors.lastname: Linker
authors.forename: C A
authors.initials: CA
authors.lastname: Schiffer
authors.forename: P H
authors.initials: PH
authors.lastname: Wiernik
authors.forename: D J
authors.initials: DJ
authors.lastname: Weisdorf
authors.forename: K R
authors.initials: KR
authors.lastname: Rai
mesh_terms: D000293:Adolescent; D000328:Adult; D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003697:Delphi Technique; D004305:Dose-Response Relationship, Drug; D006650:Histocompatibility Testing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis; D014019:Tissue Donors
chemical_list: D000970:Antineoplastic Agents